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Amyloid β-protein (Aβ) containing amyloid plaques and abnormal phosphorylated τ-protein con-
taining neurofibrillary tangles (NFTs) are hallmark lesions of Alzheimer’s disease. Both Aβ plaques
and NFTs show hierarchical patterns in which the areas of the brain are subsequently affected by
Aβ plaques and NFTs, respectively (Braak and Braak, 1991; Thal et al., 2002). Aβ plaques start to
develop in the neocortex (phase 1) and spread from there into allocortical regions (phase 2), dien-
cephalon, basal forebrain and striatum (phase 3), midbrain and medulla oblongata (phase 4), and
finally into the pons and the cerebellum (phase 5) (Thal et al., 2002). The first NFTs in the brain
hemispheres are found in the transentorhinal cortex (stage I), then in the entorhinal cortex (stage
II), the hippocampus (stage III), the temporal cortex (stage IV), further neocortical areas except
the primary fields (stage V), and, finally, also in primary cortical areas, such as the primary visual
cortex (stage VI) (Braak and Braak, 1991). Axonal connections between subsequently affected brain
regions suggest that AD pathology spreads along neuronal pathways (Thal et al., 2002; Braak and
Del Tredici, 2011).
Insufficient clearance of Aβ has been considered to play an essential role in the pathogenesis
of AD. Clearance mechanisms that contribute to Aβ elimination from brain are cellular enzy-
matic proteolysis in glial cells, neurons or in the extracellular space (Qiu et al., 1998; Yamaguchi
et al., 1998; Iwata et al., 2000; Thal et al., 2000; Farris et al., 2003), transport through the blood-
brain barrier (Shibata et al., 2000; Ito et al., 2007), and perivascular drainage (Weller et al., 2008)
(Figure 1A).
Here, I will discuss the potential impact of impaired Aβ clearance on propagation mechanisms
for Aβ and τ.
Biophysical and Biochemical Prerequisites for Aβ and τ Protein
Aggregation
Biophysically, protein aggregation takes place once a critical concentration of proteins has been
passed. Fibril formation sets in after a concentration-dependent lag-phase, i.e., the time interval
between passing a critical concentration and forming fibrils (Figure 1B) (Chirita et al., 2005).
Within the lag-phase, assembly of proteins into non-fibrillar intermediates, i.e., oligomers of all
sizes, precedes fibril formation (Thal et al., 2015). Proteins in general differ in their capability to
aggregate, and their assembly can be further modulated by chaperones (Gething and Sambrook,
1992). Posttranslational modifications of proteins, such as N-terminal truncation and pyrogluta-
mate formation, phosphorylation, or glycation increase the tendency of Aβ or τ to form aggre-
gates (Necula and Kuret, 2004; Schlenzig et al., 2009; Kumar et al., 2011). Seeds of preaggregated
fibrils can reduce the lag-phase dramatically and trigger immediate aggregation (Figure 1B).
Thal Clearance and spreading in AD
FIGURE 1 | Schematic representation of Aβ clearance and
propagation. (A) Aβ clearance mechanisms: enzymatic clearance within
neurons (N) and glial cells [here shown in the example is an astrocyte (AG)] or
in the extracellular space (ECS) (Qiu et al., 1998; Yamaguchi et al., 1998;
Iwata et al., 2000; Thal et al., 2000; Farris et al., 2003); transport through the
blood-brain barrier (BBB) into the blood (red arrow) (Shibata et al., 2000; Ito
et al., 2007); drainage into the perivascular space (green arrow) (Weller et al.,
2008). (B) Aβ aggregation into fibrils shows a lag-phase that is reduced by
the presence of seeds (Thal et al., 2015). (C) Initiation of Aβ fibril formation in
the presence of seeds starts immediately after a critical concentration is
passed even for a short period of time. In the absence of seeds a longer
increase of Aβ concentration may be necessary to pass the lag-phase for
initiating Aβ aggregation. (D) Influence of clearance rate, Aβ-production and
its composition [presence of modified forms of Aβ that are cleared less
effectively than normal Aβ (Russo et al., 2002; Kumar et al., 2012)] on a
potentially critical concentration of Aβ for disease progression. N-terminal
truncated, pyroglutamate-modified Aβ is less soluble than non-modified
full-length Aβ (Schlenzig et al., 2009). In other words, this modification of Aβ
modified its critical concentration for aggregation. (E) Propagation of AD
pathology, e.g., Aβ plaques, takes place when seeds of Aβ are transported to
a second primarily non-involved brain region. As soon as the concentration
of Aβ passes a critical level Aβ aggregation and fibril formation takes place,
leading to the deposition of Aβ plaques in the secondarily affected brain
region.
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In other words, a prerequisite for Aβ and/or τ protein aggrega-
tion is either a sufficient concentration of Aβ or τ over a period of
time long enough to pass the respective lag-phase or the presence
of preaggregated seeds to start aggregation as soon as the critical
protein concentration has been reached.
Aβ Clearance Modulates Concentration
and Onset of Fibril Formation of Aβ
Sufficient Aβ clearance is required to prevent an increase of
the Aβ concentration. In the absence of preaggregated Aβ seeds
a short-term increase of Aβ concentration not exceeding the
lag-phase may not start the aggregation process. Accordingly,
a “long-term” elevation of Aβ concentration is required to ini-
tiate the process of Aβ aggregation under normal conditions
(Figures 1B,C). As soon as preaggregated Aβ seeds are present
aggregation of Aβ will be initiated once the critical Aβ concen-
tration has been passed as demonstrated in animal models for Aβ
deposition (Meyer-Luehmann et al., 2006) (Figure 1C).
Impairment of Aβ Clearance by Modified
Forms and/or Aβ Intermediates
Posttranslationally modified forms of Aβ are cleared less effi-
ciently from the brain as shown for N-terminal truncated and
pyroglutamate-modified Aβ and phosphorylated Aβ (Russo et al.,
2002; Kumar et al., 2012) (Figure 1D). Oligomeric Aβ interme-
diates are stable and quite resistant to degeneration (Viola and
Klein, 2015). Moreover, Aβ oligomers alter proteasomal clear-
ance (Cecarini et al., 2012). Accordingly, it is tempting to spec-
ulate that even low amounts of Aβ intermediates and fibrils as
well as posttranslational modifications of Aβ foster disease pro-
gression not only by acting as seeds but also by their property of
impairing physiological Aβ clearance and, thereby, increasing Aβ
concentration.
Spreading of Aβ Pathology
Spreading of Aβ pathology means that Aβ aggregation and depo-
sition already took place at least in the neocortex and a second
region becomes involved in this process. Preaggregated neocorti-
cal Aβmay be transported into secondarily affected brain regions
by glial cells or neurons or by diffusion (Guo and Lee, 2014;
Thal et al., 2015). In the event that seeds prevail in a given brain
region Aβ aggregation will be initiated as soon as a critical con-
centration has been passed (Figure 1E). Given the prevalence of
cortical Aβ plaques (i.e., aggregated Aβ) in most elderly individu-
als (Braak et al., 2011) it is tempting to speculate that progression
of Aβ pathology into further brain regions can be triggered by
insufficient local clearance and subsequently increased Aβ levels
and by seeding its aggregation. If so, continuously lowering Aβ
concentration to avoid even short-term increases might be effec-
tive in preventing propagation of Aβ pathology, similar to the
inactivation of Aβ seeds as shown for continuous Aβ antibody
treatment in Aβ-producing mice (Paganetti et al., 2013).
Aβ and τ
Animal experiments in τ-transgenic mice have demonstrated
that injecting Aβ or crossbreeding these animals with Aβ-
producing amyloid precursor protein transgenic mice accelerates
and increases τ-pathology (Gotz et al., 2001; Lewis et al., 2001).
Moreover, anti-Aβ antibody treatment reduced τ-pathology in
an Aβ and τ-pathology producing mouse model (Oddo et al.,
2004). As such, it is tempting to speculate that there is cross-
seeding of τ-pathology by Aβ aggregates in vivo similar as in vitro
(Lasagna-Reeves et al., 2010). Arguments against relevant cross-
seeding of Aβ and τ in the AD brain may be (a) that τ aggregates
are intracellular aggregates while Aβ plaques are extracellular
protein aggregates, and (b) Aβ plaques develop first in the neo-
cortex whereas NFTs are found in this part of the brain only in
advanced stages of AD. However, Aβ also occurs intracellularly
(Gouras et al., 2000) and τ aggregates are transported through the
extracellular space (Kfoury et al., 2012), indicating that an inter-
action of τ and Aβmay be possible either intra- or extracellularly.
Moreover, as discussed for Aβ, a sufficient protein concentra-
tion is essential for the initiation of protein aggregation. Accord-
ingly, cross-seeding of τ by Aβ cannot take place if there is not
enough aggregation-prone τ protein even in the presence of huge
amounts of Aβ seeds. Such a constellation may apply for neocor-
tical brain regions in early stages of AD. Therefore, it seems to be
likely that cross-seeding of Aβ and τ contributes to the develop-
ment of AD and may be modulated by changing the clearance of
Aβ. Cross-seeding of Aβ and τ does not exclude the independent
aggregation of τ, as τ-aggregates have been shown to trigger the
initiation of τ-pathology (Clavaguera et al., 2009).
Conclusion
The hypothesis that insufficient Aβ clearance contributes to
the development of AD does not contradict a major role of
preaggregated Aβ and/or τ seeds in the propagation of the
disease. Moreover, improving Aβ clearance, e.g., by enhanc-
ing its enzymatic degradation or vaccination strategies, may be
capable of slowing down disease propagation given the rele-
vance of Aβ as a substrate for the protein aggregation process
in AD.
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